Activity

Filter

Cancel
Date Panel Item Activity
14 actions
Hypertrophic cardiomyopathy v5.17 SVIL Eleanor Williams Publications for gene: SVIL were set to 39966646
Hypertrophic cardiomyopathy v5.16 SVIL Eleanor Williams Added comment: Comment on publications: PMID:36778260 is a preprint of PMID:39966646
Hypertrophic cardiomyopathy v5.16 SVIL Eleanor Williams Publications for gene: SVIL were set to 39966646
Hypertrophic cardiomyopathy v5.15 SVIL Eleanor Williams Publications for gene: SVIL were set to PMID: 36778260
Hypertrophic cardiomyopathy v5.14 SVIL Ida Ertmanska Phenotypes for gene: SVIL were changed from HCM to hypertrophic cardiomyopathy, MONDO:0005045
Hypertrophic cardiomyopathy v5.13 SVIL Ida Ertmanska Classified gene: SVIL as Amber List (moderate evidence)
Hypertrophic cardiomyopathy v5.13 SVIL Ida Ertmanska Gene: svil has been classified as Amber List (Moderate Evidence).
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska changed review comment from: Comment on list classification: The main piece of evidence for this gene-disease association is a GWAS study, with very limited co-segregation evidence (PMID: 39966646). There are no other cases reported with Hypertrophic cardiomyopathy and heterozygous variants in SVIL. Individuals homozygous for nonsense variants in SVIL have been reported, but the myopathy presentation includes very mild to no cardiac involvement (PMID: 32779703). Based on available evidence, this gene should be rated Amber for Hypertrophic cardiomyopathy, until more evidence emerges.; to: Comment on list classification: The main piece of evidence for this gene-disease association is a GWAS study, with no clinical details and limited co-segregation evidence (PMID: 39966646). There are no other cases reported with Hypertrophic cardiomyopathy and heterozygous variants in SVIL. Individuals homozygous for nonsense variants in SVIL have been reported, but the myopathy presentation includes very mild to no cardiac involvement (PMID: 32779703). Based on available evidence, this gene should be rated Amber for Hypertrophic cardiomyopathy, until more evidence emerges.
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska edited their review of gene: SVIL: Added comment: Comment on list classification: The main piece of evidence for this gene-disease association is a GWAS study, with very limited co-segregation evidence (PMID: 39966646). There are no other cases reported with Hypertrophic cardiomyopathy and heterozygous variants in SVIL. Individuals homozygous for nonsense variants in SVIL have been reported, but the myopathy presentation includes very mild to no cardiac involvement (PMID: 32779703). Based on available evidence, this gene should be rated Amber for Hypertrophic cardiomyopathy, until more evidence emerges.; Changed rating: AMBER
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska changed review comment from: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL.
Limited evidence of cosegregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

PMID: 32779703 Hedberg-Oldfors et al., 2020
Report of 2 unrelated consanguineous families with myopathy with myofibrillar disorganization, homozygous for truncating variants in SVIL. Very mild cardiac involvement: Slightly hypertrophic left ventricular wall 2/4, slight tricuspid regurgitation 2/4; Increased basal wall thickness (30mm) in Individual 1 - noted on cardiac MRI at age 27.

Functional evidence:
PMID: 25633252 Deo et al., 2014: Morpholino knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).; to: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL. Numerous other rare nonsense variants in SVIL were also reported in the non-HCM control cohort (see supplementary table 19).
Limited evidence of segregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

PMID: 32779703 Hedberg-Oldfors et al., 2020
Report of 2 unrelated consanguineous families with myopathy with myofibrillar disorganization, homozygous for truncating variants in SVIL. Very mild cardiac involvement: Slightly hypertrophic left ventricular wall 2/4, slight tricuspid regurgitation 2/4; Increased basal wall thickness (30mm) in Individual 1 - noted on cardiac MRI at age 27.

Functional evidence:
PMID: 25633252 Deo et al., 2014: Morpholino knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska changed review comment from: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL.
Limited evidence of cosegregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

Functional evidence:
PMID: 25633252 Deo et al., 2014: Morpholino knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).; to: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL.
Limited evidence of cosegregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

PMID: 32779703 Hedberg-Oldfors et al., 2020
Report of 2 unrelated consanguineous families with myopathy with myofibrillar disorganization, homozygous for truncating variants in SVIL. Very mild cardiac involvement: Slightly hypertrophic left ventricular wall 2/4, slight tricuspid regurgitation 2/4; Increased basal wall thickness (30mm) in Individual 1 - noted on cardiac MRI at age 27.

Functional evidence:
PMID: 25633252 Deo et al., 2014: Morpholino knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska changed review comment from: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL.
Limited evidence of cosegregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).; to: PMID: 36778260 (2023 pre-print) / PMID: 39966646 Tadros et al., 2025 (published)
GWAS study suggesting rare truncating SVIL variants are associated with high risk of hypertrophic cardiomyopathy. 8 individuals from the HCM cohort were found to carry heterozygous nonsense variants in SVIL.
Limited evidence of cosegregation: variant SVIL:p.(Arg1616Ter) was carried by two siblings with HCM; variant SVIL:p.(Gln255Ter) was carried by two cousins with HCM in another family.

Functional evidence:
PMID: 25633252 Deo et al., 2014: Morpholino knockdown of SVIL causes cardiac edema as well as noticeable spinal curvature at higher morhpolino doses.

The pLI score for SVIL is 0.12, LOEUF = 0.48 - no strong prediction of dosage sensitivity.
This gene is only associated with AR Myofibrillar myopathy 10, 619040 in OMIM (accessed 24th Nov 2025).
Hypertrophic cardiomyopathy v5.12 SVIL Ida Ertmanska reviewed gene: SVIL: Rating: RED; Mode of pathogenicity: None; Publications: 36778260, 39966646; Phenotypes: hypertrophic cardiomyopathy, MONDO:0005045; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Hypertrophic cardiomyopathy v4.7 SVIL Dmitrijs Rots gene: SVIL was added
gene: SVIL was added to Hypertrophic cardiomyopathy. Sources: Literature
Mode of inheritance for gene: SVIL was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for gene: SVIL were set to PMID: 36778260
Phenotypes for gene: SVIL were set to HCM
Review for gene: SVIL was set to AMBER
Added comment: In the novel paper described:"the excess burden is even greater at 15.3-fold (95% CI: 5.7-41.3; P:7x10−7) when restricting the analysis to high confidence LoF variants affecting the predominant SVIL transcript in LV (ENST00000375400) (Supplementary Table 6b). In one family, the SVIL LoF variant (p.(Gln255*)) was carried by two cousins with HCM (parents deceased), providing some evidence of co-segregation. Taken together, these data support SVIL as a novel HCM disease gene."
Strong statistical evidence + one family segregating.
Sources: Literature